Regular blood glucose monitoring, liver function tests, and lipid panels provide important safety data
In a clinical study involving 1,651,452 patients with type 2 diabetes, semaglutide decreased the development of 10 out of 13 obesity-associated cancers, which include the following: Colorectal cancer Meningioma Endometrial cancer Gallbladder cancer Multiple myeloma Kidney cancer Ovarian cancer Pancreatic cancer Esophageal cancer Hepatocellular carcinoma These results suggest that GLP-1 receptor agonists can protect against cancer
For those experiencing persistent side effects, alternative GLP-1 receptor agonists or other glucose-lowering therapies may be considered
Only then will you feel like a completely new person
Together, we can embark on this journey to better health
References Sarzi-Puttini P, Giorgi V, Marotto D, Atzeni F